You are here

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Some concerns from Turkey’ by Bilgin et al
  1. Yuko Kaneko1,
  2. Hideto Kameda1,2,
  3. Kei Ikeda3,
  4. Tomonori Ishii4,
  5. Kosaku Murakami5,
  6. Hyota Takamatsu6,
  7. Yoshiya Tanaka7,
  8. Takayuki Abe8,
  9. Tsutomu Takeuchi1
  1. 1 Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
  2. 2 Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan
  3. 3 Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan
  4. 4 Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan
  5. 5 Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan
  6. 6 Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan
  7. 7 The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
  8. 8 Department of Preventive Medicine and Public Health, Biostatistics at Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan
  1. Correspondence to Professor Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; tsutake{at}z5.keio.jp
View Full Text

http://dx.doi.org/10.1136/annrheumdis-2018-214776

Statistics from Altmetric.com

    We would like to thank Bilgin et al 1 for their interest in our paper2 and asking several questions for clarification.

    First, we allowed non-steroidal anti-inflammatory drugs (NSAIDs) in this trial, except for the 6 weeks (from 2 weeks prior to the initiation of trial drugs until 4 weeks) during which NSAIDs were allowed only for fever, in order to assess the status of body temperature appropriately.

    Second, the per cent change in glucocorticoid dose were compared between the placebo and tocilizumab groups by means of analysis …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

    Linked Articles

    • Correspondence
      Some concerns from Turkey
      Emre Bilgin İrem Ozarli Levent Kılıç Ertuğrul Çağrı Bölek Gözde Kübra Yardımcı Ömer Karadağ
      Annals of the Rheumatic Diseases 2018; 79 e15-e15 Published Online First: 24 Nov 2018. doi: 10.1136/annrheumdis-2018-214739